General Information of Drug (ID: DMTSIYZ)

Drug Name
CVN058 Drug Info
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMTSIYZ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting 5-HT 3 receptor (5HT3R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ondansetron DMOTQ1I Chemotherapy-induced nausea MD90 Approved [3]
Granisetron DMIUW25 Malignant glioma 2A00.0 Approved [4]
Ramosetron DMH7GN8 Diarrhea-predominant irritable bowel syndrome DD91.01 Approved [5]
Y-25130 DMDPM7R Nausea and vomiting MD90 Approved [6]
Renzapride DM7HQNX Irritable bowel syndrome DD91.0 Phase 3 [7]
LITOXETINE DMKZRBP Mood disorder 6A60-6E23 Phase 3 [8]
Zatosetron maleate DMWDEFC Anxiety disorder 6B00-6B0Z Phase 3 [9]
Pancopride DMIRYU9 Nausea MD90 Phase 3 [10]
Lerisetron DMOTCIU Nausea MD90 Phase 3 [11]
Lintopride DMSHGWN Nausea MD90 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 3 receptor (5HT3R) TTNXLKE NOUNIPROTAC Antagonist [2]

References

1 ClinicalTrials.gov (NCT03669250) CVN058 Effect on Mismatch Negativity in Schizophrenics. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Cerevance.
3 Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol. 1998 Oct;10(10):865-70.
4 New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J. 2006 Sep-Oct;12(5):341-7.
5 Inhibitory effect of YM060 on 5-HT3 receptor-mediated depolarization in colonic myenteric neurons of the guinea pig. Eur J Pharmacol. 1995 Sep 5;283(1-3):107-12.
6 The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist. Eur J Pharmacol. 1991 Apr 24;196(3):299-305.
7 Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63.
8 Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. Eur J Pharmacol. 1993 Mar 2;232(2-3):139-45.
9 Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. J Clin Psychopharmacol. 1999 Apr;19(2):125-31.
10 Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis. Eur J Pharmacol. 1992 Nov 10;222(2-3):257-64.
11 Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
12 The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.